JHBP/Genor (嘉和生物) IPO Trading: Visible Upsides
JHBP/Genor raised HKD 2,694 million (USD 348 m) from its global offering and will list on the Hong Kong Stock Exchange tomorrow. In our previous...
411 Views
Gilead: Will Immunomedics Be Gilead’s Next Pharmasset?
Gilead Sciences announced on 13th September that it has entered into a definitive agreement to acquire Immunomedics for US$88.00 per share in cash,...
363 Views
ECM Weekly (27 September 2020) - Ant Group, Chindata, SCG Packaging, JHBP/Genor, Neuedu, UTI AMC
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Deal...
437 Views
JHBP/Genor (嘉和生物) IPO: Undemanding Valuation with a Strong Investor Line-Up
JHBP/Gencor Biopharmaceutical (hereafter Gencor) is a China-based biotech company with a focus on oncology and autoimmune drugs with development...
505 Views
GoodRx IPO: A Healthy Prescription for Strong Topline Growth and Profits
GoodRx (GDRX) offers a prescription aggregation platform in the US enabling healthcare professionals to provide prices from the platform directly...
404 Views